Phentermine plus topiramate in the treatment of obesity
(Impact Factor: 45.22).
07/2011; 378(9786):125-6; author reply 126-7. DOI: 10.1016/S0140-6736(11)61080-5
Available from: John Y L Chiang
- "This distinguishes ER-b–selective ligands from most of the new chemical entities under development [e.g., Lorcarserin (Arena Pharmaceuticals), Qnexa (Vivus Inc.), and Contrave (Orexigen Ltd.)], which reduce body weight by suppressing appetite through targets in the central nervous system. Unfortunately, many anti-obesity drugs belonging to similar classes were eventually withdrawn from the market due to cardiovascular side effects (Connolly et al., 1997; Malgarini and Pimpinella, 2011). Since long-term activation of ER-a could have unwarranted side effects (e.g., thromboembolism and breast and uterine cancers), we examined the effects of ER-b–selective agonists on the hypothalamus– pituitary–gonadal axis in males fed a high-fat diet and on uterine weight in females with ovariectomy-induced weight gain to ensure the absence of cross-reactivity with ER-a. "
[Show abstract] [Hide abstract]
ABSTRACT: This article is a report on a symposium sponsored by the American Society for Pharmacology and Experimental Therapeutics and held at the Experimental Biology 12 meeting in San Diego, CA. The presentations discussed the roles of a number of nuclear receptors in regulating glucose and lipid homeostasis, the pathophysiology of obesity-related disease states and the promise associated with targeting their activities to treat these diseases. While many of these receptors, in particular constitutive androstane receptor and pregnane X receptor and their target enzymes have been thought of as regulators of drug and xenobiotic metabolism, this symposium highlighted the advances made in our understanding of the endogenous functions of these receptors. Similarly, the advances made in our understanding of the mechanisms underlying bile acid signaling pathways in the regulation of body weight and glucose homeostasis illustrates the importance of using complementary approaches to elucidate this fascinating network of pathways. The observations that some receptors, like the farnesoid X receptor can function in a tissue specific manner via well defined mechanisms has important clinical implications particularly in the treatment of liver diseases. Finally, the novel findings that agents that selectively activate estrogen receptor β can effectively inhibit weight gain in a high-fat diet model of obesity identifies a new role for this member of the steroid superfamily. Taken together, this symposium has revealed a number of significant findings that illustrate the promise associated with targeting a number of nuclear receptors for the development of new therapies to treat obesity and other metabolic disorders.
Drug metabolism and disposition: the biological fate of chemicals 10/2012; 41(1). DOI:10.1124/dmd.112.048694 · 3.25 Impact Factor
Available from: saolucas-se.com.br
Circulation Cardiovascular Quality and Outcomes 07/2012; 5(4):580-6. DOI:10.1161/CIRCOUTCOMES.111.964072 · 5.66 Impact Factor
Available from: Ariane Conrad
[Show abstract] [Hide abstract]
ABSTRACT: Obesity is now a major public health concern worldwide with increasing prevalence and a growing list of comorbidities and complications. The morbidity, mortality and reduced productivity associated with obesity and its complications result in a major burden to health care costs. Obesity is a complex chronic medical syndrome often with multiple different etiologic factors in individual patients. The long term successful management of obesity remains particularly challenging and invariably requires a multifaceted approach including lifestyle and behavioral modification, increased physical activity, and adjunctive pharmacotherapy. Bariatric surgery remains a last resort though at present it has the best results for achieving sustained robust weight loss. Obesity pharmacotherapy has been very limited in its role for long term obesity management because of the past history of several failed agents as well as the fact that presently available agents are few, and generally utilized as monotherapy. The recent FDA approval of the fixed drug combination of phentermine and extended release topiramate (topiramate-ER) (trade name Qsymia™) marks the first FDA approved combination pharmacotherapeutic agent for obesity since the Phen-Fen combination of the 1990s. This review details the history and clinical trial basis for the use of both phentermine and topiramate in obesity therapeutics as well as the results of clinical trials of their combination for obesity treatment in humans. The initial clinical approval trials offer evidence that this fixed drug combination offers synergistic potential for effective, robust and sustained weight loss with mean weight loss of at least 10% of baseline achieved and sustained for up to 2 years in over 50% of subjects treated. It is anticipated that this agent will be the first in a new trend of multi-agent combination therapy for the chronic adjunctive management of obesity.
Drug Design, Development and Therapy 04/2013; 7:267-78. DOI:10.2147/DDDT.S31443 · 3.03 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.